# Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

> **NCT01954251** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 829 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster vaccine GSK 1437173A
- **BIOLOGICAL:** GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A

## Key facts

- **NCT ID:** NCT01954251
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-03
- **Primary completion:** 2014-06-02
- **Final completion:** 2015-03-20
- **Target enrollment:** 829 (ACTUAL)
- **Last updated:** 2018-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954251, "Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01954251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*